Trial Profile
A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) Versus Raltegravir (RAL) Each Administered With a Background Regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2021
Price :
$35
*
At a glance
- Drugs Elvitegravir (Primary) ; Raltegravir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Jul 2012 Integrase resistance results presented at the 19th International AIDS Conference.